| Peer-Reviewed

Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder

Received: 3 July 2016     Accepted: 25 August 2016     Published: 28 October 2016
Views:       Downloads:
Abstract

The regional cerebral blood flow (rCBF) and the cerebral vasoreactivity of the patients with depressive disorder were observed by SPECT and acetazolamide stress SPECT test respectively. Eighteen unmedicated depressed patients and nineteen healthy control subjects were included. Baseline SPECT was performed in both patients and control subjects. Acetazolamide stress SPECT test was performed two days later in patients two hours after taking 2g acetazolamide orally. It was found that there was significant difference between the untreated depressed patients and the controls, because there was relatively reduced perfusion in frontal lobe, temporal lobe, left parietal lobe and right basal ganglia in depressed patients. After acetazolamide stress SPECT test, the perfusion of decreased regions in baseline step was increased. No potential ischemic lesion was found. The perfusion of some specific regions of the depressed patients decreased. Acetazolamide stress SPECT test could not reveal silent brain ischemia in the depressed patients. The perfusion of decreased regions in the baseline imaging was increased in acetazolamide stress SPECT test.

Published in Advances in Applied Physiology (Volume 1, Issue 3)
DOI 10.11648/j.aap.20160103.11
Page(s) 38-42
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2016. Published by Science Publishing Group

Keywords

Depression, Regional Cerebral Blood Flow, SPECT, Acetazolamide

References
[1] Neu, P., P. Schlattmann, A. Schilling, and A. Hartmann, Cerebrovascular reactivity in major depression: a pilot study. Psychosom Med, 2004, 66 (1): 6-8.
[2] Devantier, T. A., B. L. Norgaard, M. K. Poulsen, E. Garde, K. A. Ovrehus, M. Marwan, S. Achenbach, D. Dey, L. H. Sorensen, and P. Videbech, White Matter Lesions, Carotid and Coronary Atherosclerosis in Late-Onset Depression and Healthy Controls. Psychosomatics, 2016.
[3] Kaichi, Y., G. Okada, M. Takamura, S. Toki, Y. Akiyama, T. Higaki, Y. Matsubara, Y. Okamoto, S. Yamawaki, and K. Awai, Changes in the regional cerebral blood flow detected by arterial spin labeling after 6-week escitalopram treatment for major depressive disorder. J Affect Disord, 2016, 194: 135-43.
[4] Ota, M., T. Noda, N. Sato, K. Hattori, T. Teraishi, H. Hori, A. Nagashima, K. Shimoji, T. Higuchi, and H. Kunugi, Characteristic distributions of regional cerebral blood flow changes in major depressive disorder patients: a pseudo-continuous arterial spin labeling (pCASL) study. J Affect Disord, 2014, 165: 59-63.
[5] Chen, Z. Q., M. Y. Du, Y. J. Zhao, X. Q. Huang, J. Li, S. Lui, J. M. Hu, H. Q. Sun, J. Liu, G. J. Kemp, and Q. Y. Gong, Voxel-wise meta-analyses of brain blood flow and local synchrony abnormalities in medication-free patients with major depressive disorder. J Psychiatry Neurosci, 2015, 40 (6): 401-11.
[6] Gonul, A. S., M. Kula, A. G. Bilgin, A. Tutus, and A. Oguz, The regional cerebral blood flow changes in major depressive disorder with and without psychotic features. Prog Neuropsychopharmacol Biol Psychiatry, 2004, 28 (6): 1015-21.
[7] Vangu, M. D., J. D. Esser, I. H. Boyd, and M. Berk, Effects of electroconvulsive therapy on regional cerebral blood flow measured by 99mtechnetium HMPAO SPECT. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27 (1): 15-9.
[8] Bhardwaj, R., S. Chakrabarti, B. R. Mittal, and P. Sharan, A single photon emission computerized tomography (SPECT) study of regional cerebral blood flow in bipolar disorder. World J Biol Psychiatry, 2010, 11 (2 Pt 2): 334-43.
[9] Kawakatsu, S. and A. Komatani, [Xe-133 inhalation single photon emission computerized tomography in manic-depressive illness]. Nihon Rinsho, 1994, 52 (5): 1180-4.
[10] 1Hosokawa, T., T. Momose, and K. Kasai, Brain glucose metabolism difference between bipolar and unipolar mood disorders in depressed and euthymic states. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33 (2): 243-50.
[11] Vagal, A. S., J. L. Leach, M. Fernandez-Ulloa, and M. Zuccarello, The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia. AJNR Am J Neuroradiol, 2009, 30 (5): 876-84.
[12] Kojima, T., S. Mizumura, S. I. Kumita, H. Nakajo, T. Kumazaki, T. Kitamura, K. Fukino, and A. Teramoto, Regional cerebral blood flow and vascular reserve in neuronal migration disorder assessed by Tc-99m hexamethylpropylene amineoxime SPECT with acetazolamide challenge. Clin Nucl Med, 2000, 25 (9): 749-50.
[13] Saeed, A., M. Al-Rashida, M. Hamayoun, A. Mumtaz, and J. Iqbal, Carbonic anhydrase inhibition by 1-aroyl-3-(4-aminosulfonylphenyl) thioureas. J Enzyme Inhib Med Chem, 2014, 29(6):901-5.
[14] Granero, G. E., M. R. Longhi, C. Becker, H. E. Junginger, S. Kopp, K. K. Midha, V. P. Shah, S. Stavchansky, J. B. Dressman, and D. M. Barends, Biowaiver monographs for immediate release solid oral dosage forms: acetazolamide. J Pharm Sci, 2008, 97 (9): 3691-9.
[15] Oishi, M., Y. Mochizuki, and T. Takasu, Cerebral blood flow and cerebrovascular response to acetazolamide in patients with chronic alcoholism. J Neurol Neurosurg Psychiatry, 1997, 63 (1): 100-2.
[16] Bonne, O. and Y. Krausz, Pathophysiological significance of cerebral perfusion abnormalities in major depression-trait or state marker? Eur Neuropsychopharmacol, 1997, 7 (3): 225-33.
Cite This Article
  • APA Style

    Yi Xu, Jian Gong, Hao Xu. (2016). Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder. Advances in Applied Physiology, 1(3), 38-42. https://doi.org/10.11648/j.aap.20160103.11

    Copy | Download

    ACS Style

    Yi Xu; Jian Gong; Hao Xu. Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder. Adv. Appl. Physiol. 2016, 1(3), 38-42. doi: 10.11648/j.aap.20160103.11

    Copy | Download

    AMA Style

    Yi Xu, Jian Gong, Hao Xu. Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder. Adv Appl Physiol. 2016;1(3):38-42. doi: 10.11648/j.aap.20160103.11

    Copy | Download

  • @article{10.11648/j.aap.20160103.11,
      author = {Yi Xu and Jian Gong and Hao Xu},
      title = {Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder},
      journal = {Advances in Applied Physiology},
      volume = {1},
      number = {3},
      pages = {38-42},
      doi = {10.11648/j.aap.20160103.11},
      url = {https://doi.org/10.11648/j.aap.20160103.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.aap.20160103.11},
      abstract = {The regional cerebral blood flow (rCBF) and the cerebral vasoreactivity of the patients with depressive disorder were observed by SPECT and acetazolamide stress SPECT test respectively. Eighteen unmedicated depressed patients and nineteen healthy control subjects were included. Baseline SPECT was performed in both patients and control subjects. Acetazolamide stress SPECT test was performed two days later in patients two hours after taking 2g acetazolamide orally. It was found that there was significant difference between the untreated depressed patients and the controls, because there was relatively reduced perfusion in frontal lobe, temporal lobe, left parietal lobe and right basal ganglia in depressed patients. After acetazolamide stress SPECT test, the perfusion of decreased regions in baseline step was increased. No potential ischemic lesion was found. The perfusion of some specific regions of the depressed patients decreased. Acetazolamide stress SPECT test could not reveal silent brain ischemia in the depressed patients. The perfusion of decreased regions in the baseline imaging was increased in acetazolamide stress SPECT test.},
     year = {2016}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Acetazolamide Stress SPECT Test on Cerebral Blood Flow in Patients with Depressive Disorder
    AU  - Yi Xu
    AU  - Jian Gong
    AU  - Hao Xu
    Y1  - 2016/10/28
    PY  - 2016
    N1  - https://doi.org/10.11648/j.aap.20160103.11
    DO  - 10.11648/j.aap.20160103.11
    T2  - Advances in Applied Physiology
    JF  - Advances in Applied Physiology
    JO  - Advances in Applied Physiology
    SP  - 38
    EP  - 42
    PB  - Science Publishing Group
    SN  - 2471-9714
    UR  - https://doi.org/10.11648/j.aap.20160103.11
    AB  - The regional cerebral blood flow (rCBF) and the cerebral vasoreactivity of the patients with depressive disorder were observed by SPECT and acetazolamide stress SPECT test respectively. Eighteen unmedicated depressed patients and nineteen healthy control subjects were included. Baseline SPECT was performed in both patients and control subjects. Acetazolamide stress SPECT test was performed two days later in patients two hours after taking 2g acetazolamide orally. It was found that there was significant difference between the untreated depressed patients and the controls, because there was relatively reduced perfusion in frontal lobe, temporal lobe, left parietal lobe and right basal ganglia in depressed patients. After acetazolamide stress SPECT test, the perfusion of decreased regions in baseline step was increased. No potential ischemic lesion was found. The perfusion of some specific regions of the depressed patients decreased. Acetazolamide stress SPECT test could not reveal silent brain ischemia in the depressed patients. The perfusion of decreased regions in the baseline imaging was increased in acetazolamide stress SPECT test.
    VL  - 1
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Clinical Psychology, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Clinical Psychology, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Department of Clinical Psychology, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Sections